Lady Davis Carmel Medical Center

Haifa 3436212

7 studies enrolling now · 44 studies all time

What they study most

Acute Non-cardioembolic Ischemic Stroke, Atrial Fibrillation, Autologous Stem Cell Transplant, Bladder Cancer, Bronchiectasis, Candidemia, Cardiovascular Diseases, Chronic Lymphocytic Leukemia, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Diabetes Mellitus, Type 2

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis — Recruiting now
• A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast — Recruiting now
• A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — Recruiting now
• Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) — Recruiting now
• A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer — Recruiting now
• Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis — Recruiting now
• A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer — Recruiting now
• A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma — Recruiting now
• Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine — Running, not enrolling
• Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis — Running, not enrolling
• A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis — Completed
• Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — Running, not enrolling
• A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) — Completed
• A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Running, not enrolling
• Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) — Completed
• Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma — Completed
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia — Completed
• A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease — Stopped early
• Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients — Running, not enrolling
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) — Completed
• A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke — Completed
• Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies — Completed
• Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye — Completed
• Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% — Completed
• A Study to Investigate Leramistat in Patients With IPF — Withdrawn before enrolling
• An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants — Stopped early
• EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) — Completed
• A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant — Completed
• A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — Stopped early
• Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis — Completed
• A Study Evaluating the Long-term Safety of VX-445 Combination Therapy — Completed
• Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) — Completed
• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) — Stopped early
• A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) — Completed
• Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis — Completed
• A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma — Completed
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care — Stopped early
• Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria — Stopped early
• A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy — Stopped early
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) — Completed
• A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) — Completed
• Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) — Completed
• Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis — Completed